A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)
A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma
Sponsor: SecuraBio
This PHASE2 trial investigates Indolent Non-Hodgkin Lymphoma and is currently completed. SecuraBio leads this study, which shows 14 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Apr 2023 — Oct 2023 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 9 earlier versions
-
Apr 2021 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2019 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- SecuraBio
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Atlanta, United States , Baltimore, United States , Barcelona, Spain , Bologna, Italy , Bordeaux, France , Boston, United States , Brescia, Italy , Brest, Belarus , Brno, Czechia and 53 more locations